RESEARCH ARTICLE Accrual to a randomised t a

Full list of author information is available at the end of the articleBackground Brain metastases (BMs) are common in patients with metastatic melanoma [1,2] and are the cause of death in the majority of them [2,3]. Whole brain radiotherapy (WBRT) is a common adjuvant treatment after local treat-ment of BMs with neurosurgery and/or stereotactic radiation (SR). However, there is no level one evidence to support this approach in melanoma. Proponents say that WBRT improves palliation by prolonging intracerebral con-trol [4]. Opponents say that WBRT does not increase sur-vival, may cause neurocognitive problems and may not prevent intracerebral progression [5,6]. A randomised con-trolled trial (RCT) is needed to resolve this controversy. Based on trials of WBRT in BMs of all histologies, an ac-crual target of two hundred patients for the RCT was con